Literature DB >> 2792327

Treatment of a patient in a relapse after bone marrow transplantation for acute lymphoblastic leukemia with the systemic administration of allogeneic lymphokine-activated killer cells and recombinant interleukin-2.

T Komori, H Sugiyama, H Ogawa, Y Oka, S Miyake, T Soma, Y Tani, Y Minami, K Kunisada, T Masaoka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2792327     DOI： 10.1111/j.1600-0609.1989.tb00277.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  2 in total

1.  Over-expression of aldehyde dehydrogenase-2 protects against H₂O₂-induced oxidative damage and apoptosis in peripheral blood mononuclear cells.

Authors:  Xiu-ying Hu; Qin Fang; Ji-shi Wang; Jian-qiong Xie; Bai-sheng Chai; Fang-qiong Li; Xin Cui; Yuan Yang
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

2.  Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.

Authors:  B J Boughton; A W Simpson; T A Phaure; C Beatty
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.